^
Association details:
| Biomarker: | PIK3CA E545K |
|---|---|
| Cancer: | Hormone Receptor Positive Breast Cancer |
| Drug: | RLY-2608 (pan-mutant PIK3CA-selective inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
RLY-2608: The first allosteric mutant- and isoform-selective inhibitor of PI3Ka, is efficacious as a single agent and drives regressions in combination with standard of care therapies in PIK3CA mutant breast cancer models
Published date:
10/09/2021
Excerpt:
We performed in vitro combinations in two HR+ PIK3CA mutant cell lines (MCF7: E545K; T47D: H1047R) and observed synergy between RLY-2608 and fulvestrant or CDK4/6 inhibitors…the triple combination of RLY2608, fulvestrant, and abemaciclib resulted in superior efficacy compared to either the RLY-2608 + fulvestrant or RLY-2608 + abemaciclib doublets, with deep regressions observed in the triple combination arm.
Secondary therapy:
fulvestrant
